Alexion Reports Third Quarter 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Cowen Remains Bullish Following Alexion Pharma's (ALXN) 3Q
October 29, 2015 1:14 PM EDTCowen reiterated an Outperform rating and $216.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) following the company's 3Q earnings report. Alexion reported Q3 Soliris sales of $665.4MM vs. consensus $666MME and nonGAAP EPS of $1.16 vs. $1.01E.
Analyst Eric Schmidt commented, "Alexion reported Q3... More
Alexion Pharma (ALXN) Tops Q3 EPS by 15c; Guides Above Views
October 29, 2015 7:52 AM EDTAlexion Pharma (NASDAQ: ALXN) reported Q3 EPS of $1.16, $0.15 better than the analyst estimate of $1.01. Revenue for the quarter came in at $666.6 million versus the consensus estimate of $668.33 million.
Alexion Pharma sees FY2015 EPS of $4.92-$4.97, versus the consensus of $4.82.
The third... More
